Miltefosine (Impavido): the first oral treatment against leishmaniasis

@article{Sindermann2003MiltefosineT,
  title={Miltefosine (Impavido): the first oral treatment against leishmaniasis},
  author={Herbert Sindermann and Simon L. Croft and Kirsten R Engel and Wolfgang Bommer and Hansjörg Eibl and Clemens Unger and Juergen Prof Engel},
  journal={Medical Microbiology and Immunology},
  year={2003},
  volume={193},
  pages={173-180}
}
Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy. 

[Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis].

TLDR
The criteria used were pad measurements and investigations of amastigotes and cultures after treatment with glucamine and oral miltefosine, which indicated that milteFosine was similar to or better than glucamine.

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.

TLDR
Repeated responses after relapse and tolerability of long courses of treatment indicate the potential for development of optimized dosage schemes.

Miltefosine and cutaneous leishmaniasis

TLDR
An important advantage of this drug is its oral administration when compared with the standard parenteral drugs in the context of a large-scale use in the inner regions of the endemic countries.

Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.

  • C. SchranerB. Hasse H. Günthard
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
We describe here a case of disseminated cutaneous leishmaniasis due to Leishmania major in a severely immunocompromised patient from Burkino Faso, Africa, who is infected with human immunodeficiency

Estudo comparativo entre miltefosina oral e antimoniato de N-metil glucamina parenteral no tratamento da leishmaniose experimental causada por Leishmania (Leishmania) amazonensis

Twenty-five mice were infected with Leishmania amazonensis and treated with glucamine and oral miltefosine. The criteria used were pad measurements and investigations of amastigotes and cultures

A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis

TLDR
In this pilot randomized clinical trial, M+P treatment and A-P treatment yielded similar cure rates, and the former was associated with a lower risk of AEs, and future studies with more patients and longer follow-up are recommended.
...

References

SHOWING 1-10 OF 58 REFERENCES

Miltefosine--the long-awaited therapy for visceral leishmaniasis?

  • B. Herwaldt
  • Medicine
    The New England journal of medicine
  • 1999
Miltefosine was originally developed as an antineoplastic drug, but it has the potential to become the first highly effective, orally administered drug for treating visceral leishmaniasis, a life-t...

Antileishmanial activity of the ether phospholipid ilmofosine.

Short-course of oral miltefosine for treatment of visceral leishmaniasis.

  • S. SundarA. Makharia H. Murray
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2000
TLDR
A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days, 21 days, or 28 days, and cure was achieved in 89% of groups A, 100% of group B, and 100%" of group C.

Immunochemotherapy of visceral leishmaniasis: a pilot trial of sequential treatment with recombinant interferon-gamma and pentavalent antimony.

TLDR
IFN-gamma was well tolerated in the dose tested and may be very effective as an adjunct to conventional therapy with antimony.

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.

TLDR
Orally administered miltefosine appears to be an effective treatment for Indian visceral leishmaniasis.

Trial of oral miltefosine for visceral leishmaniasis

Suppression of Posttreatment Recurrence of Experimental Visceral Leishmaniasis in T-Cell-Deficient Mice by Oral Miltefosine

  • H. Murray
  • Medicine, Biology
    Antimicrobial Agents and Chemotherapy
  • 2000
TLDR
Intracellular visceral infection recurred in untreated mice but was suppressed by once- or twice-weekly oral administration of miltefosine, which may be useful as oral maintenance therapy for T-cell-deficient patients with visceral leishmaniasis.

Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies.

Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India.

Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.

  • J. SotoJ. Toledo J. Berman
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2001
TLDR
In this uncontrolled study of oral miltefosine for treatment of patients with American cutaneous leishmaniasis, a dosage of approximately 2.25 mg/kg/day for 3-4 weeks was effective and tolerated.
...